Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Thermo Fisher Scientific Inc

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Thermo Fisher Scientific is in Stage 2, the uptrend phase, now in week 10 (since Aug 18, 2026). It closed at $676.54, 2.9% below its 52-week high and above its 200-day average, which is rising.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. More about the company

$676.54
-2.84% today
$250B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is TMO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 21w
S4 17w
S2 20w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 6w → S4 12w → S1 5w → S2 21w → S3 7w → S2 11w → S3 3w → S4 10w → S1 8w → S4 17w → S1 10w → S2 20w → S3 7w → S4 14w → S1 5w → S2 9w current
Total tracked: 166 weeks across 16 stage runs.

TMO among Diagnostics & Research19th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…19TMOStage 2 · wk 1071+1.7%
vs 52W High
-2.9%
$437.57 lo$696.49 hi
2.9% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 10
1w13w26w
Week 10, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
23.4%
200 DMA: $548.25 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.70x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+1.7%
3M
+19.1%
6M
+45.2%
YTD
+14.5%
1Y
+21.7%
Scan Membership
Breakout Watch
Latest: 2024-08-14
8 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 10 · Vol 1.70x
2026-10-21S2
Wk 10 · Vol 1.58x
2026-10-20S2
Wk 9 · Vol 1.72x
2026-10-19S2
Wk 9 · Vol 1.17x
2026-10-16S2
Wk 9 · Vol 1.03x
2026-10-15S2
Wk 9 · Vol 1.99x
2026-10-14S2
Wk 9 · Vol 1.26x
2026-10-13S2
Wk 8 · Vol 1.17x
2026-10-12S2
Wk 8 · Vol 0.70x
2026-10-09S2
Wk 8 · Vol 0.79x
2026-10-08S2
Wk 8 · Vol 1.30x
2026-10-07S2
Wk 8 · Vol 0.90x
Moving averages & range
50 DMA
$643.24
200 DMA
$548.25
52W High
$696.49
52W Low
$437.57
5D Low
$676.54
Resistance levels (recent highs)
20d High
$696.49
60d High
$696.49
120d High
$696.49
250d High
$696.49
Next resistance
+2.9%
to 20d High
P/E (TTM)
35.7
Forward 24.4
Earnings Growth (YoY)
+8.7%
Revenue +9.1%
ROE
+13.4%
Profit margin +14.9%
Dividend Yield
0.27%
P/B 4.6

Thermo Fisher Scientific: quick answers

What stage is Thermo Fisher Scientific in?

As of Oct 22, 2026, Thermo Fisher Scientific (TMO) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 18, 2026 and is in week 10. What the four stages mean

Is Thermo Fisher Scientific in an uptrend?

Yes. Thermo Fisher Scientific is in a Stage 2 uptrend. It trades 23.4% above its 200-day average, which is rising.

How far is Thermo Fisher Scientific from its 52-week high?

Thermo Fisher Scientific closed at $676.54 on Oct 22, 2026, 2.9% below its 52-week high of $696.49. Its 52-week low is $437.57.

How has Thermo Fisher Scientific performed over the past year?

As of Oct 22, 2026, Thermo Fisher Scientific is up 21.7% over the past year and up 14.5% so far in 2026.

Which sector and industry is Thermo Fisher Scientific in?

Thermo Fisher Scientific is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.